Home › Cancro dello stomaco › Pennsylvania › Pittsburgh
Studi clinici su Cancro dello stomaco a Pittsburgh, PA
14 studi su Cancro dello stomaco cercano partecipanti presso sedi a Pittsburgh e dintorni (entro circa 30 miglia). Apri uno studio per vedere chi può partecipare e come contattare il team.
Testo ufficiale dello studio (inglese)
Stai reclutando per uno studio? Mettilo in evidenza in cima alla pagina — $99 per 30 giorni →
Distance-Based Exercise to Preserve Function and Prevent Disability
In reclutamento
- UPMC Hillman Cancer Center, Pittsburgh
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)
In reclutamentoFase 2/3
- UPMC Hillman Cancer Center, Pittsburgh
A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma
In reclutamentoFase 2
- Research Site, Pittsburgh
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
In reclutamentoFase 1
- University of Pittsburgh Medical Center, Pittsburgh
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
In reclutamentoFase 1/2
- Allegheny Health Network, Pittsburgh
SKL35501 With SKL35502 Imaging in Adults With NTSR1 Positive Advanced Solid Tumors
In reclutamentoFase 1
- UPMC Hillman Cancer Center, Pittsburgh
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
In reclutamentoFase 3
- Research Site, Pittsburgh
- Research Site, Pittsburgh
A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
In reclutamentoFase 1/2
- University of Pittsburgh Medical Center, Pittsburgh
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
In reclutamentoFase 1/2
- Research Site, Pittsburgh
A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors
In reclutamentoFase 1
- University of Pittsburg Medical Center _UPMC Hillman Cancer Center, Pittsburgh
Lead-212 PSV359 Therapy for Patients With Solid Tumors
In reclutamentoFase 1/2
- University of Pittsburgh Medical Center, Pittsburgh
A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer
In reclutamentoFase 3
- UPMC Hillman Cancer Center, Pittsburgh
Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies
In reclutamentoFase 1/2
- UPMC Hillman Cancer Center, Pittsburgh
Intra-tumoral (IT) Injection of vvDD-hIL2-2-RG-1 for Metastatic Gastrointestinal and Peritoneal Tumors
In reclutamentoFase 1
- AHN West Penn Hospital, Pittsburgh
Studi su Cancro dello stomaco in altre città
- Houston, TX42 studi
- Boston, MA32 studi
- New York City, NY31 studi
- Nashville, TN28 studi
- Baldwin Park, CA22 studi
- Los Angeles, CA22 studi
- Arlington, VA20 studi
- Dallas, TX19 studi
- San Antonio, TX19 studi
- Grand Rapids, MI18 studi
- St. Louis, MO18 studi
- Washington, DC16 studi
Altri studi a Pittsburgh
- Cancro del polmone non a piccole cellule48 studi
- Cancro (tutti i tipi)41 studi
- Cancro al seno39 studi
- Cancro colorettale32 studi
- Cancro metastatico31 studi
- Melanoma31 studi
- Cancro ovarico30 studi
- Cancro dell'endometrio23 studi
- Cancro alla prostata23 studi
- Cancro ai polmoni23 studi
- Carcinoma a cellule squamose della testa e del collo22 studi
- Ictus22 studi
Fonte: ClinicalTrials.gov, dati recuperati il 6 ott 2026. Ogni studio stabilisce i propri criteri di idoneità; è il team di ricerca a decidere chi può partecipare.